Invention Grant
- Patent Title: Compound having PD-L1 expression-suppressing action
-
Application No.: US17602331Application Date: 2020-04-08
-
Publication No.: US11591297B2Publication Date: 2023-02-28
- Inventor: Haruhisa Kikuchi , Yoshiteru Oshima , Toshio Hattori , Osamu Yamada , Jing Zhang , Shinya Kida , Shinya Murase
- Applicant: TOHOKU UNIVERSITY , JUNSEI EDUCATIONAL INSTITUTION , FUSO PHARMACEUTICAL INDUSTRIES, LTD.
- Applicant Address: JP Sendai; JP Okayama; JP Osaka
- Assignee: TOHOKU UNIVERSITY,JUNSEI EDUCATIONAL INSTITUTION,FUSO PHARMACEUTICAL INDUSTRIES, LTD.
- Current Assignee: TOHOKU UNIVERSITY,JUNSEI EDUCATIONAL INSTITUTION,FUSO PHARMACEUTICAL INDUSTRIES, LTD.
- Current Assignee Address: JP Sendai; JP Okayama; JP Osaka
- Agency: Cantor Colburn LLP
- Priority: JPJP2019-074077 20190409
- International Application: PCT/JP2020/015771 WO 20200408
- International Announcement: WO2020/209277 WO 20201015
- Main IPC: C07D211/60
- IPC: C07D211/60 ; A61P35/00

Abstract:
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.
Public/Granted literature
- US20220194900A1 NOVEL COMPOUND HAVING PD-L1 EXPRESSION-SUPPRESSING ACTION Public/Granted day:2022-06-23
Information query